The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Randomized, Single Blind Trial of Intravenous versus Oral Steroid Monotherapy in Graves’ Orbitopathy
Abstract
CONTEXT: Glucocorticoids are effective for severe Graves' orbitopathy (GO), which causes substantial morbidity. The question at issue is how best to use them. OBJECTIVE: The objective of this study was to optimize glucocorticoid application in GO. DESIGN: The study design was a randomized trial over 12 wk with 6-month follow-up. SETTING: The study was performed at university joint thyroid and ophthalmic clinics. PATIENTS: Seventy euthyroid out-patients with untreated, active, and severe GO were studied. INTERVENTION: Patients received either once weekly iv methylprednisolone (0.5 g, then 0.25 g, 6 wk each) or oral prednisolone starting with 0.1 g/d, then tapering the dose by 0.01 g/wk. MAIN OUTCOME MEASURES: At 3 months, the primary end point was a composite of improvements in proptosis, lid fissure width, and rate of diplopia in primary gaze, visual acuity, eye muscle thickness, and patient's quality of life. RESULTS: Intravenous glucocorticoid therapy resulted in rapid, significant, and sustained improvement. At 3 months, 27 of 35 patients (77%) in the iv group had a treatment response compared with 18 of 35 (51%) in the oral group (P < 0.01). Improvements over baseline values for disease severity (e.g. visual acuity; P = 0.01) and activity (e.g. chemosis; P < 0.01) and for quality of life (P < 0.001) were greater in the iv group. TSH receptor antibody titers decreased during iv steroid administration (P < 0.001), and smoking had a strong impact on the therapy response (P < 0.001). Additional treatment was required less frequently in the iv group. Intravenous steroids were safe, with different rates of adverse events between the two groups (P < 0.001). CONCLUSIONS: In patients with active and severe GO, iv glucocorticoids were more effective and better tolerated than oral steroids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring Health-Related Quality of Life
Guyatt, G. H., Feeny, D. H., & Patrick, D. L. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-8-199304150-00009 · Cited by 3,958
Assessment of Quality-of-Life Outcomes
Testa, M. A., & Simonson, D. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603283341306 · Cited by 2,551
Management of Graves’ Ophthalmopathy: Reality and Perspectives*
Bartalena, L., Pinchera, A., & Marcocci, C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0393 · Cited by 677
Current Perspective on the Pathogenesis of Graves’ Disease and Ophthalmopathy
Prabhakar, B. S., Bahn, R. S., & Smith, T. J. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0020 · Cited by 489
Human peripheral blood contains two distinct lineages of dendritic cells
Robinson, S. P., Patterson, S., English, N., Davies, D., Knight, S. C., & Reid, C. D. L. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199909)29:09<2769::aid-immu2769>3.0.co;2-2 · Cited by 373
Marcocci, C. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3562 · Cited by 309
Pathophysiology of Graves’ Ophthalmopathy: The Cycle of Disease
Bahn, R. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-030010 · Cited by 229
Prummel, M., Bakker, A., Wiersinga, W., Baldeschi, L., Mourits, M., Kendall-Taylor, P., Perros, P., Neoh, C., Dickinson, A., Lazarus, J., et al. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480491 · Cited by 213
Self-citationDickinson, A. J., & Perros, P. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01349.x · Cited by 210
MOLECULAR MECHANISMS OF GLUCOCORTICOIDS IN THE CONTROL OF INFLAMMATION AND LYMPHOCYTE APOPTOSIS
Tuckermann, J. P., Kleiman, A., McPherson, K. G., & Reichardt, H. M. (2005) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360590888983 · Cited by 202
Cited by
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0479 · Cited by 1,054
Self-citationBartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G. J., Marcocci, C., Perros, P., Salvi, M., & Wiersinga, W. M. (2016) · European Thyroid Journal · doi:10.1159/000443828 · Cited by 943
Self-citationConsensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO
Bartalena, L., Baldeschi, L., Dickinson, A., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Mourits, M., Perros, P., Boboridis, K., Boschi, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0666 · Cited by 795
Self-citationBartalena, L., Baldeschi, L., Dickinson, A. J., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Mourits, M. P., Perros, P., Boboridis, K., Boschi, A., et al. (2008) · Thyroid · doi:10.1089/thy.2007.0315 · Cited by 406
Self-citationDavies, T. F., Andersen, S., Latif, R., Nagayama, Y., Barbesino, G., Brito, M., Eckstein, A. K., Stagnaro-Green, A., & Kahaly, G. J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0184-y · Cited by 398
Self-citationIntravenous Glucocorticoids for Graves' Orbitopathy: Efficacy and Morbidity
Zang, S., Ponto, K. A., & Kahaly, G. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1962 · Cited by 379
Self-citationBartalena, L., Krassas, G. E., Wiersinga, W., Marcocci, C., Salvi, M., Daumerie, C., Bournaud, C., Stahl, M., Sassi, L., Veronesi, G., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2389 · Cited by 370
Randomized Controlled Trial of Rituximab in Patients With Graves' Orbitopathy
Stan, M. N., Garrity, J. A., Carranza Leon, B. G., Prabin, T., Bradley, E. A., & Bahn, R. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2572 · Cited by 369
Bartalena, L., & Tanda, M. L. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0806317 · Cited by 336
New insights into the pathogenesis and nonsurgical management of Graves orbitopathy
Taylor, P. N., Zhang, L., Lee, R. W. J., Muller, I., Ezra, D. G., Dayan, C. M., Kahaly, G. J., & Ludgate, M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0305-4 · Cited by 315
Self-citationSalvi, M., Vannucchi, G., Campi, I., Currò, N., Dazzi, D., Simonetta, S., Bonara, P., Rossi, S., Sina, C., Guastella, C., et al. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02325 · Cited by 264
Metadata
- Authors
- Kahaly, G. J., Pitz, S., Hommel, G., & Dittmar, M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-09
- Volume
- 90
- Issue
- 9
- Pages
- 5234-5240
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2066663435
- Cited by
- 423
- References
- 31
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.